Pluri

Company Overview

Snapshot

Founded in January 2003, Pluri operates with 201–500 employees and has raised a total of $136.9M across 13 funding rounds from 4 investors. The company became publicly traded on NASDAQ in April 2003, marking a significant milestone in its journey.

Business overview

Pluri develops cell-based products for commercial applications, focusing on global well-being and sustainability. The company's core technology is a patented and validated 3D cell expansion system, which enables the advancement of novel cell-based solutions across various initiatives, including medicine, climate change, food scarcity, and animal welfare. Pluri's method is designed for accuracy, scalability, cost-effectiveness, and batch-to-batch consistency. Currently active in regenerative medicine and food technology, Pluri seeks partnerships to leverage its 3D cell-based technology in other industries requiring mass cell production.

Strategic signal

In October 2025, Pluri's subsidiary Coffeesai announced a strategic collaboration with Instituto del Café de Chiapas to advance cell-based coffee manufacturing in Mexico. This partnership signals Pluri's strategic expansion beyond traditional regenerative medicine into sustainable food technology, demonstrating the versatility of its 3D cell expansion platform and opening new market opportunities in the agricultural sector.

Company Intelligence Q&A

What was a significant recent collaboration for Pluri's subsidiary Coffeesai?

In October 2025, Pluri's subsidiary Coffeesai announced a strategic collaboration with Instituto del Café de Chiapas to advance cell-based coffee manufacturing in Mexico.

What was Pluri's financial performance in the first quarter of 2025?

In November 2024, Pluri reported a first-quarter 2025 earnings loss of US$1.08 per share, compared to a US$0.96 loss in the first quarter of 2024.

What new immunotherapy platform did Pluri launch in May 2024?

In May 2024, Pluri launched a novel immunotherapy platform focused on unleashing the power of MAIT Cells for solid tumor cancer treatment.

What strategic partnership did Pluri form with Bar-Ilan University?

In October 2024, Pluri collaborated with Bar-Ilan University to advance cancer immunotherapy for solid tumors, a project supported by the Israel Innovation Authority.

What was Pluri's full-year earnings report for 2023?

In September 2023, Pluri reported a full-year 2023 earnings loss of US$0.77 per share, an improvement from the US$1.28 loss in fiscal year 2022.